ThromboGenics NV (THR)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:ThromboGenics NV (THR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8012300
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月14日
◆ページ数:52
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:ベルギー
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥33,750見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥67,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥101,250見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
ThromboGenics NV (ThromboGenics) is a biotechnology company, which develops and commercializes ophthalmic and cancer medicines. The company’s ocriplasmin, a recombinant derivative of the plasmin protein, is commercialized as Jetrea in the US to treat symptomatic vitreomacular adhesion (VMA) and vitreomacular traction (VMT). ThromboGenics’s product pipeline includes THR-409 (ocriplasmin) under evaluation for inducing total posterior vitreous detachment in patients with non-proliferative diabetic retinopathy; THR-317 for diabetic macular edema; THR-687 and THR-149 for diabetic retinopathy. ThromboGenics spun off its oncology research in a joint venture with VIB (Flanders Institute for Biotechnology) into Oncurious NV, which focuses on the treatment of pediatric brain tumors. It has a presence in Belgium, Ireland and the US. ThromboGenics is headquartered in Leuven, Flemish Brabant, Belgium.

ThromboGenics NV (THR) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
ThromboGenics NV, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
ThromboGenics NV, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
ThromboGenics NV, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
ThromboGenics NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
ThromboGenics NV, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
ThromboGenics NV, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
ThromboGenics Forms Joint Venture with VIB 10
Licensing Agreements 11
Oncurious Enters into Licensing Agreement with VIB 11
ThromboGenics Enters into Licensing Agreement with Galapagos 12
ThromboGenics Enters into Licensing Agreement with Grifols 13
ThromboGenics Enters Into Licensing Agreement With Bicycle Therapeutics 14
Equity Offering 15
ThromboGenics Plans to Raise USD11.8 Million in Private Placement of Shares 15
ThromboGenics Completes Private Placement Of Shares For US$103.7 Million 16
ThromboGenics NV – Key Competitors 18
ThromboGenics NV – Key Employees 19
ThromboGenics NV – Locations And Subsidiaries 20
Head Office 20
Other Locations & Subsidiaries 20
Recent Developments 21
Financial Announcements 21
Sep 07, 2017: ThromboGenics Business Update – H1 2017 21
Mar 16, 2017: ThromboGenics Business Update – FY 2016 25
Oct 20, 2016: ThromboGenics Business Update – Q3 2016 29
Aug 25, 2016: ThromboGenics Business Update- H1 2016 32
Corporate Communications 36
Nov 08, 2017: ThromboGenics Strengthens Leadership Team 36
Jun 15, 2017: Thomas Clay Appointed Chairman of the Board of Directors 37
Product News 38
04/20/2017: Thrombogenics Achieves Important Milestone In The Development Of THR-149, A Novel Plasma Kallikrein Inhibitor For Diabetic Macular Edema 38
Product Approvals 39
Jan 07, 2016: BioInvent announces FDA acceptance of the Investigational New Drug application for the phase I/IIa study with TB-403 39
Other Significant Developments 40
Oct 20, 2017: ThromboGenics Business Update – Q3 2017 40
May 11, 2017: ThromboGenics Business Update – Q1 2017 43
May 13, 2016: ThromboGenics Business Update – Q1 2016 46
May 13, 2016: ThromboGenics Business Update – Q1 2016 49
Appendix 52
Methodology 52
About GlobalData 52
Contact Us 52
Disclaimer 52

List of Tables
ThromboGenics NV, Pharmaceuticals & Healthcare, Key Facts, 2016 2
ThromboGenics NV, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
ThromboGenics NV, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
ThromboGenics NV, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
ThromboGenics NV, Deals By Therapy Area, 2011 to YTD 2017 8
ThromboGenics NV, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
ThromboGenics Forms Joint Venture with VIB 10
Oncurious Enters into Licensing Agreement with VIB 11
ThromboGenics Enters into Licensing Agreement with Galapagos 12
ThromboGenics Enters into Licensing Agreement with Grifols 13
ThromboGenics Enters Into Licensing Agreement With Bicycle Therapeutics 14
ThromboGenics Plans to Raise USD11.8 Million in Private Placement of Shares 15
ThromboGenics Completes Private Placement Of Shares For US$103.7 Million 16
ThromboGenics NV, Key Competitors 18
ThromboGenics NV, Key Employees 19
ThromboGenics NV, Other Locations 20
ThromboGenics NV, Subsidiaries 20

★海外企業調査レポート[ThromboGenics NV (THR)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • U.S. Venture Inc:企業の戦略的SWOT分析
    U.S. Venture Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servi …
  • InTouch Technologies Inc:医療機器:M&Aディール及び事業提携情報
    Summary InTouch Technologies Inc (InTouch Health) is a healthcare technology company that provides Telehealth Network, comprised of telehealth systems, clinical workflow solutions, software and managed services to healthcare systems and hospitals for the delivery of clinical care. The company’s tele …
  • PACCAR Inc (PCAR):企業の財務・戦略的SWOT分析
    PACCAR Inc (PCAR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Pro Petroleum Inc:企業の戦略的SWOT分析
    Pro Petroleum Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • Inventec Corporation (2356):企業の財務・戦略的SWOT分析
    Inventec Corporation (2356) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Visa Inc:企業のM&A・事業提携・投資動向
    Visa Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Visa Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital …
  • Tokyo Electric Power Company Holdings Incorporated (9501)-エネルギー分野:企業M&A・提携分析
    Summary Tokyo Electric Power Company Holdings, Incorporated (TEPCO), formerly Tokyo Electric Power Company, Incorporated, is an integrated energy company. The company generates, transmits, distributes and sells electricity through its subsidiaries. It generates power from various sources such as the …
  • Severstal:企業の戦略・SWOT・財務情報
    Severstal - Strategy, SWOT and Corporate Finance Report Summary Severstal - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • Brioche Pasquier S.A.:企業の戦略・SWOT・財務分析
    Brioche Pasquier S.A. - Strategy, SWOT and Corporate Finance Report Summary Brioche Pasquier S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Commonwealth Bank of Australia:企業のM&A・事業提携・投資動向
    Commonwealth Bank of Australia - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Commonwealth Bank of Australia Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers a …
  • Delfasco, LLC:企業の戦略・SWOT・財務情報
    Delfasco, LLC - Strategy, SWOT and Corporate Finance Report Summary Delfasco, LLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Oando Energy Resource Inc:石油・ガス:M&Aディール及び事業提携情報
    Summary Oando Energy Resource Inc (Oando), a subsidiary of Oando Plc, is an exploration and production company that carries out upstream exploration and development programs. The company provides investments in a portfolio of oil and gas fields, and provides participation of interests in onshore and …
  • Astronics Corporation:戦略・SWOT・企業財務分析
    Astronics Corporation - Strategy, SWOT and Corporate Finance Report Summary Astronics Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Regency Centers Corporation:企業のM&A・事業提携・投資動向
    Regency Centers Corporation - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Regency Centers Corporation Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acq …
  • KAZ Minerals PLC:企業の戦略・SWOT・財務情報
    KAZ Minerals PLC - Strategy, SWOT and Corporate Finance Report Summary KAZ Minerals PLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Canadian Western Bank Group (CWB):企業の財務・戦略的SWOT分析
    Canadian Western Bank Group (CWB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • YTL Corporation Berhad:企業の戦略・SWOT・財務分析
    YTL Corporation Berhad - Strategy, SWOT and Corporate Finance Report Summary YTL Corporation Berhad - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • AliveCor Inc:医療機器:M&Aディール及び事業提携情報
    Summary AliveCor Inc (AliveCor) is a heart rate measuring technology provider. The company offers kardia mobile and kardia application. It provides medical-grade EKG in just thirty seconds. AliveCor’s kardia offers easy to use, affordable, portable and trusted. The company track data over time and m …
  • Tox Free Solutions Limited (TOX):企業の財務・戦略的SWOT分析
    Tox Free Solutions Limited (TOX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Zhejiang Hisoar Pharmaceutical Co Ltd (002099):製薬・医療:M&Aディール及び事業提携情報
    Summary Zhejiang Hisoar Pharmaceutical Co Ltd (Hisoar) is a pharmaceutical company that offers specialty raw materials, preparations, fine chemicals, dyes and intermediates. The company offers raw drugs such as antibody, anti-virus, sugar-reducing, cardiovascular and worm-driven drugs. It produces f …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆